Evinacumab Cuts Cholesterol Levels by Half in Patients with HoFH

Monoclonal antibody effective for the full spectrum of homozygous familial hypercholesterolemia

Contact: Nicole Napoli, nnapoli@acc.org, 202-375-6523

WASHINGTON (Mar 30, 2020) -

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled trial of the drug, which is being presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Homozygous familial hypercholesterolemia (HoFH) is an inherited condition characterized by extremely high cholesterol levels from birth. Many patients with HoFH develop coronary artery disease and face a high risk of heart attacks and other cardiac events even before reaching age 20.

“For the first time, we were able to get these patients with HoFH to remarkably normal LDL cholesterol levels,” said Frederick J. Raal, PhD, head of the Division of Endocrinology and Metabolism at the University of Witwatersrand, Johannesburg, South Africa, and lead author of the Phase 3 trial. “It’s the most potent cholesterol-lowering drug we’ve seen for this very difficult-to-treat group of patients.”

Patients with HoFH usually have two defective copies of the LDL receptor gene that is the main cause of the disorder and typically have LDL cholesterol levels that are increased four-fold or more compared to those with only one defective gene (heterozygous FH) whose LDL cholesterol are about twice normal. To keep LDL cholesterol levels in check, most patients with HoFH take a combination of three medications—a “triple therapy” that consists of a high intensity statin, a PCSK9 inhibitor and ezetimibe, a drug that limits the absorption of cholesterol from the intestine. If those measures are insufficient, patients undergo lipoprotein apheresis to mechanically remove excess LDL cholesterol from the blood, a costly procedure that many patients undergo several times per month.

Evinacumab is a monoclonal antibody that binds to angiopoietin-like protein 3 (ANGPTL3), a protein thought to play a role in cholesterol metabolism. Subjects with low or absent ANGPLT3 due to a genetic cause have very low cholesterol levels and rarely suffer from atherosclerotic cardiovascular disease. By targeting ANGPTL3, evinacumab is designed to reduce cholesterol through a different mechanism than any existing drug.

Researchers enrolled 65 patients with HoFH. About three-quarters of the patients were on triple therapy and one-third were also on regular apheresis at the start of the trial. Patients continued their regular therapy throughout the study. Two-thirds of patients were randomly assigned to receive evinacumab via intravenous infusion every four weeks for 24 weeks, while one-third of participants received placebo infusions.

Patients receiving evinacumab had a striking reduction in LDL cholesterol starting at week two. At week 24, average LDL cholesterol levels among those receiving evinacumab had plummeted by 47.1% while LDL cholesterol levels among those receiving placebo rose by 1.9%, resulting in an average relative reduction of 49% among those receiving evinacumab, meeting the trial’s primary endpoint.

In terms of absolute LDL cholesterol levels, patients receiving evinacumab had an average drop of 132 mg/dL. Nearly a half of those receiving evinacumab achieved an LDL cholesterol below 100 mg/dL.

“The results are remarkable,” Raal said. “This is a promising add-on therapy for individuals with homozygous FH that addresses the unmet need to further lower LDL cholesterol in these patients.”

Reductions in LDL cholesterol with evinacumab were similar in HoFH patients with absent LDL receptor function (null/null) and in those with some residual LDL receptor function (non-null). This is of major clinical significance, as null/null HoFH patients have the highest cardiovascular risk and are least responsive to currently available lipid-lowering drugs, Raal said.

Adverse events were fairly common, occurring in 65.9% of patients receiving evinacumab and 81% of those receiving placebo. The most common adverse events were a cold, headache, fever, diarrhea and toothache. No serious adverse events were considered to be related to the study treatment, Raal said.

The relatively short duration of treatment and the small number of patients limit the trial’s ability to draw conclusions regarding the long-term safety of evinacumab. The researchers plan to continue the study with an open-label extension to determine longer-term safety of evinacumab in this difficult-to-treat population.

The trial was funded by Regeneron Pharmaceuticals, Inc., maker of evinacumab.

ACC.20/WCC will take place March 28-30, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC20/#WCCardio for the latest news from the meeting.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.


< Back to Listings